Trial Profile
A Phase 1 Open-label, Radiolabeled, Single-Dose Study To Investigate The Absorption, Distribution, Metabolism, And Excretion Of [14c]PF-06463922 In Healthy Male Volunteers
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 26 May 2020
Price :
$35
*
At a glance
- Drugs Lorlatinib (Primary)
- Indications Cancer; Neuroblastoma; Non-small cell lung cancer
- Focus Pharmacokinetics
- Sponsors Pfizer
- 22 May 2020 Results from NCT03184168 and NCT02564562 evaluating Metabolism, Excretion, and Pharmacokinetics of Lorlatinib (PF-06463922) and Evaluation of the Impact of Radiolabel Position and Other Factors on Comparability, published in the Journal of Clinical Pharmacology
- 16 Mar 2019 Comparison of data from the 2 ADME studies conducted for lorlatinib presented at the 120th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics.
- 03 Dec 2015 Status changed from recruiting to completed as reported by ClinicalTrials.gov.